CDK4 and neoplasm: Tumors with low levels of CDK6 compared to CDK4 are universally sensitive to CDK4/6 inhibitors, including HR+ breast, mantle cell lymphomas, Ewing sarcomas as well as subsets of large tumor types, e.g. NSCLC.